KYMR · Categories · Downgrades
KYMR - Analyst downgrades
Kymera Therapeutics Inc. (KYMR) analyst downgrades - real-time wire coverage filtered to Downgrades only.
Recent Downgrades for KYMR
- Kymera Therapeutics downgraded by Wolfe ResearchWolfe Research downgraded Kymera Therapeutics from Outperform to Peer Perform
- Kymera Therapeutics downgraded by BofA Securities with a new price targetBofA Securities downgraded Kymera Therapeutics from Buy to Neutral and set a new price target of $30.00 from $45.00 previously
- Kymera Therapeutics downgraded by Wells Fargo with a new price targetWells Fargo downgraded Kymera Therapeutics from Overweight to Equal Weight and set a new price target of $26.00
- Kymera Therapeutics downgraded by Credit Suisse with a new price targetCredit Suisse downgraded Kymera Therapeutics from Outperform to Neutral and set a new price target of $32.00 from $47.00 previously
- Kymera Therapeutics downgraded by BofA Securities with a new price targetBofA Securities downgraded Kymera Therapeutics from Buy to Neutral and set a new price target of $80.00 from $65.00 previously